Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
SynBiotic SE is a German biotechnology company focused on the development of cannabinoid-based pharmaceuticals and therapies. Its competitive position is bolstered by a proprietary platform for cannabinoid extraction and formulation, primarily targeting the European market where regulatory frameworks are evolving to support medical cannabis applications.
SynBiotic SE generates revenue primarily through the sale of cannabinoid-based pharmaceuticals, leveraging its proprietary extraction technology to create high-purity products. The company also engages in research collaborations with larger pharmaceutical firms, providing a steady stream of income through R&D partnerships and licensing agreements.
Regulatory changes in the EU regarding medical cannabis usage
Partnership announcements with larger pharmaceutical companies
Clinical trial results for new cannabinoid therapies
Market adoption rates of cannabinoid-based treatments
Regulatory changes that could restrict cannabinoid usage
Technological advancements in alternative therapies
Emerging competitors in the cannabinoid space with superior products
Price competition from generic drug manufacturers
Negative cash flow impacting liquidity
Potential need for additional financing to support R&D
moderate - The demand for healthcare products, including pharmaceuticals, is somewhat insulated from economic cycles, but discretionary spending on wellness products can be affected by GDP fluctuations.
Interest rates impact the company's cost of capital for R&D investments and can influence investor sentiment towards biotech stocks, generally leading to lower valuations in a rising rate environment.
minimal - The company's low debt levels suggest limited exposure to credit conditions.
growth - Investors looking for exposure to the expanding medical cannabis market and innovative therapies.
high - The stock has experienced significant volatility, reflected in its recent performance metrics.
